ERBB2 and breast carcinoma: In this study, we adapted an existing, validated, discrete-event simulation model to extend the published RxPONDER trial data to estimate long-term, population-level breast cancer outcomes in women diagnosed with HR+, HER2-, node-positive (1–3 nodes) breast cancer with a RS of ≤ 25 [14, 15].